Transcend Vivoscope secures ￥100M+ in Series B+ funding to advance its high-end scientific instruments and brain-computer interface strategy

Recently, Transcend Vivoscope announced the completion of its Series B+ financing round, raising over 100 million. This round of funding was jointly invested by five institutions with strong industrial backgrounds: the Guangdong Traditional Chinese Medicine Health Equity Investment Fund, the Beijing Medical and Health Industry Investment Fund, Beijing Zhongguancun Science City Innovation Development, Haikai Holding Group, and the Tianjin Heying Haihe Brain-Machine Interface Fund.

As a high-end biomedical imaging technology platform company founded under the leadership of Academician Cheng Heping from the Chinese Academy of Sciences, Transcend Vivoscope has been dedicated to the independent research and development of China's domestically produced high-end brain science instruments since its establishment in 2016. The high-end multimodal biomedical imaging platform developed by Transcend Vivoscope has already provided key solutions for cutting-edge fields such as life sciences, clinical medicine, and brain-computer interfaces.

Standing at the new starting point of its tenth anniversary, this round of financing not only marks another significant milestone for Transcend Vivoscope in the capital market but also signifies a critical leap from technological innovation and industrial validation to ecosystem development, officially opening a new chapter of growth.

The funds raised in this round will primarily be allocated to three key areas: accelerating the development of next-generation products, deepening global market expansion, and accelerating the recruitment of top-tier talent. By strengthening its dual-driven strategy of "high-end scientific instruments + brain-computer interfaces," Transcend Vivoscope will further solidify its technological barriers, promote the widespread application of high spatiotemporal resolution neural observation technology in clinical and brain disease intervention fields, and provide robust support for the autonomous development and control of China's high-end scientific research instruments.

Transcend Vivoscope's competitive moat is built upon its comprehensive, groundbreaking advancements in "miniaturized multi-photon imaging," spanning from technological breakthroughs and core components to complete system integration.

First, global pioneering in product and technology. Transcend Vivoscope is the world's only supplier of miniaturized multi-photon microscopy imaging systems validated by long-term market application. From the world's first 2.2-gram miniaturized two-photon microscope in 2017, to the 2.17-gram miniaturized three-photon microscope enabling deep-brain imaging in 2023, and to the newly developed world's first "multicolor miniaturized two-photon microscope," Transcend Vivoscope consistently drives primary innovation, continuously pushing the boundaries of depth, clarity, and information dimensionality in live brain imaging to new extremes.

Second, complete independence and control over core components. The competition in high-end scientific instruments essentially revolves around the underlying core components. Led by an interdisciplinary team under Academician Cheng Heping, Transcend Vivoscope has achieved independent design and production of all critical core components, ranging from miniaturized probes and specialty optical fibers to femtosecond lasers and scanning devices. This not only completely breaks the long-term foreign monopoly but also ensures supply chain security and independent control over technological iteration. Moreover, it forms the fundamental guarantee for China's high-end instruments to achieve "reverse innovation" and even export to developed countries.

Third, the capability to bridge scientific research with clinical application. Leveraging its profound expertise in multi-photon technology, Transcend Vivoscope has successfully extended its technology into clinical practice. Its independently developed "In Vivo Two-Photon Microscopic Imaging System" has obtained China's first medical device registration certificate based on this principle. The clinical value of the product has been empirically validated. For example, it assisted the team at China-Japan Friendship Hospital in achieving the world's first non-invasive, pathological-level in vivo observation of melasma treatment efficacy. This breakthrough revealed the underlying reasons for the difficulty in treating melasma and its tendency to relapse, providing an empirical foundation for precise classification and treatment of melasma. The related findings were published in the top international journal JAMA Dermatology. Additionally, Transcend Vivoscope is leading the compilation of the world's first international atlas for two-photon skin disease diagnosis, marking its transition from a technology provider to an active participant in shaping clinical diagnostic standards.

In Vivo Two-Photon Microscopy Imaging System SV780

High-Precision Tomographic Imaging of the Epidermis and Superficial Dermis

Since the Series B financing, Transcend Vivoscope has not rested on its existing achievements but has instead achieved critical breakthroughs across multiple dimensions.

At the strategic level, Transcend Vivoscope has, for the first time, explicitly proposed and begun constructing a forward-looking business layout centered on "high-end scientific instruments + brain-computer interfaces." This approach deeply aligns with Transcend Vivoscope's goal of building an underlying platform and ecosystem enabler with integrated "imaging-observation-analysis" capabilities.

At the technological and product level, breakthroughs have emerged in rapid succession. The most remarkable among these is the successful development of the "multicolor miniaturized two-photon microscope." It represents the world's first achievement of high-resolution deep-brain color imaging in freely moving mice, which will significantly advance the analysis of complex neural circuits and establish a new foundation for brain disease research and brain-inspired intelligence development.

Three-dimensional Reconstruction Image of Neuronal Calcium Signals (Red), Mitochondrial Calcium Signals (Green), and Amyloid Plaques (Blue) in an Alzheimer's Disease Model Mouse

Meanwhile, the SN 50 wireless single-photon microscope has completely eliminated cable constraints; the SN SMART model has successfully targeted heavy-duty users in neuroscience and achieved batch sales; and the wide-field co-localization in vivo reflectance confocal microscope has entered the special approval process for innovative medical devices. This series of product innovations has provided a powerful engine for its global market expansion.

SUPERNOVA-50 Wireless Miniature Single-Photon Microscope

SUPERNOVA-SAMRT Miniaturized Two-Photon Microscope

At the global market level, milestones continue to be achieved. Its products have been sold to world-leading institutions such as Harvard University, Johns Hopkins University, the University of Oxford, the National Institutes of Health (NIH), the Max Planck Society, and the Salk Institute. With over a hundred units installed worldwide and tens of thousands of hours of stable operation, these systems have become essential scientific tools for analyzing neural circuits and exploring the mechanisms of brain diseases.

Recently, the global expansion has achieved another critical breakthrough: the market footprint has been extended for the first time to the United Kingdom and Canada. To support in-depth operations, an overseas company has been formally registered, and an office in Maryland, USA, has been concurrently established. This marks the evolution of Transcend Vivoscope's globalization strategy from a singular focus on "product export" to a comprehensive new phase of localized operations and services in key markets, driving a significant increase in overseas revenue.